Presentations and articles by Paul E. Marik, MD
These four resources explore Dr. Marik’s approach to understanding cancer through the relationships among genetics, cellular metabolism, the tumor microenvironment, and immune function. They examine individualized care, the achievements and limitations of targeted treatment, and the rationale for combining standard oncology with metabolic and integrative strategies.
The collection includes a two-part illustrated presentation on cancer and two companion articles focused on lung cancer. Together, they offer patients, caregivers, and healthcare professionals an introduction to the biological concepts and proposed treatment strategies discussed by the author.
Understanding Cancer: A Two-Part Presentation
Begin with these presentations for an overview of Dr. Marik’s perspective on cancer biology and integrative care.
Cancer Presentation, Part 1: Biology and Individualized Care
Presentation slides · PDF · 27 pages
The first presentation introduces An Integrative Approach to the Treatment of Cancer. Dr. Marik discusses how tumor type, disease stage, molecular characteristics, immune status, overall health, and patient preferences inform individualized care.
Topics include cancer incidence and risk factors, differences between childhood and adult cancers, hereditary cancer syndromes, driver and passenger mutations, and examples of targeted therapies. The presentation also examines treatment costs and the author’s critique of an exclusively mutation-centered understanding of cancer, introducing his broader emphasis on metabolism, the tumor microenvironment, and immunity.
Cancer Presentation, Part 2: Metabolism and Integrative Strategies
Presentation slides · PDF · 25 pages
The second presentation develops the metabolic concepts introduced in Part 1. It explores the Warburg effect, mitochondrial function, and the ability of cancer cells to adapt by using different fuels and biological pathways.
Dr. Marik presents his Five-Axis Metabolic Trap and discusses proposed roles for repurposed medications, nutraceuticals, dietary interventions, and lifestyle changes. Diagrams connect these approaches with cellular metabolism, cancer stem cells, cell division, the tumor microenvironment, and immune function. The presentation concludes with the author’s perspective on combining strategies that address several aspects of cancer biology.
A Closer Look at Lung Cancer
These companion articles move from the molecular characteristics of lung cancer to Dr. Marik’s proposed framework for addressing the biological processes associated with tumor survival and treatment resistance.
Lung Cancer in the Era of Precision Oncology — Part 1
Epidemiology, Molecular Biology, and Therapeutic Challenges
Article · PDF · 4 pages · October 3, 2026
This article reviews lung cancer risk factors, major disease subtypes, and the role of molecular profiling in selecting treatment. Particular attention is given to KRAS-mutant and EGFR-mutant non-small cell lung cancer and the distinct biology of small cell lung cancer.
Dr. Marik describes advances in targeted therapy alongside mechanisms of acquired resistance, including alternative signaling pathways, changes in tumor characteristics, and metabolic adaptation. These shared adaptive processes provide the rationale for the complementary framework introduced in Part 2.
Lung Cancer Beyond Precision Oncology — Part 2
The Five-Axis Metabolic Trap as a Systems Biology Framework
Article · PDF · 13 pages · October 4, 2026
Building on Part 1, this article describes five interconnected areas within Dr. Marik’s proposed framework: metabolic pressure; mitochondria and cancer stem cells; cytoskeletal and mitotic disruption; tumor microenvironment modulation; and immune restoration.
The discussion brings together dietary and lifestyle interventions, repurposed medications, and nutraceuticals as proposed complements to standard lung cancer treatment. It also considers treatment costs, differences in the supporting evidence, and directions for future research. The author explicitly identifies the combined framework as investigational and states that prospective clinical validation is required.
Reading These Resources
For a broad introduction, begin with the cancer presentations. For a focused discussion of lung cancer, begin with the first article. Read Part 1 before Part 2 within either series.
The lung cancer articles describe the proposed metabolic framework as complementary to standard oncology. The author advises that decisions about off-label therapies be made with a qualified healthcare professional familiar with the patient’s medical history and current treatment plan.